Pregnane X receptor agonists impair postprandial glucose tolerance

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 6, 2013, Pages 556-563

  Rysa J ^a   Buler, M ^a   Savolainen, M J ^a,b   Ruskoaho, H ^a,c   Hakkola, J ^a   Hukkanen, J ^a,b  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA CYANOPREGNENOLONE; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; GLUCOSE TRANSPORTER 2; INSULIN; METFORMIN; REPAGLINIDE; RIFAMPICIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CONTROLLED STUDY; DIET RESTRICTION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HUMAN EXPERIMENT; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; INSULIN RESISTANCE; MALE; NONHUMAN; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ADULT; ANIMALS; C-PEPTIDE; CROSS-OVER STUDIES; DOWN-REGULATION; FEMALE; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORTER TYPE 2; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, INBRED C57BL; POSTPRANDIAL PERIOD; PREGNENOLONE CARBONITRILE; PRIMARY CELL CULTURE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, STEROID; RIFAMPIN;

EID: 84878258395     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.48     Document Type: Article

References (44)

1. Ihunnah, C.A., Jiang, M. & Xie, W. Nuclear receptor PXR, transcriptional circuits and metabolic relevance. Biochim. Biophys. Acta 1812, 956-963 (2011).
2. Hukkanen, J. Induction of cytochrome P450 enzymes: a view on human in vivo fndings. Expert Rev. Clin. Pharmacol. 5, 569-585 (2012).
3. Zollner, G., Marschall, H.U., Wagner, M. & Trauner, M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol. Pharm. 3, 231-251 (2006).
4. Konno, Y., Negishi, M. & Kodama, S. The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. Drug Metab. Pharmacokinet. 23, 8-13 (2008).
5. Nakamura, K., Moore, R., Negishi, M. & Sueyoshi, T. Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver. J. Biol. Chem. 282, 9768-9776 (2007).
6. Ma, Y. & Liu, D. Activation of pregnane X receptor by pregnenolone 16 alpha-carbonitrile prevents high-fat diet-induced obesity in AKR/J mice. PLoS One 7, e38734 (2012).
7. Sahi, J., Shord, S.S., Lindley, C., Ferguson, S. & LeCluyse, E.L. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes. J. Biochem. Mol. Toxicol. 23, 43-58 (2009).
8. Lahtela, J.T., Arranto, A.J. & Sotaniemi, E.A. Enzyme inducers improve insulin sensitivity in non-insulin-dependent diabetic subjects. Diabetes 34, 911-916 (1985).
9. Lahtela, J.T., Gachalyi, B., Eksymä, S., Hämäläinen, A. & Sotaniemi, E.A. The efect of liver microsomal enzyme inducing and inhibiting drugs on insulin mediated glucose metabolism in man. Br. J. Clin. Pharmacol. 21, 19-26 (1986).
10. Köhle, C. & Bock, K.W. Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem. Pharmacol. 77, 689-699 (2009).
11. Takasu, N. et al. Rifampicin-induced early phase hyperglycemia in humans. Am. Rev. Respir. Dis. 125, 23-27 (1982).
12. Purohit, S.D., Gupta, P.R., Agarwal, K.C., Sharma, T.N., Durlabhji, P. & Sharma, R.K. Glucose tolerance during rifampicin therapy. Ind. J. Tub. 31, 3-5 (1984).
13. Sharma, T.N., Agarwal, K.C., Gupta, P.R., Purohit, S.D., Sharma, V.K. & Mathur, B.B. Further experience on glucose tolerance test during rifampicin therapy. J. Assoc. Physicians India 34, 131-133 (1986).
14. Francois Venter, W.D., Panz, V.R., Feldman, C. & Jofe, B.I. Adrenocortical function in hospitalised patients with active pulmonary tuberculosis receiving a rifampicin-based regimen-a pilot study. S. Afr. Med. J. 96, 62-66 (2006).
15. Niemi, M., Backman, J.T., Neuvonen, M., Neuvonen, P.J. & Kivistö, K.T. Efects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin. Pharmacol. Ther. 69, 400-406 (2001).
16. Cho, S.K. et al. Rifampin enhances the glucose-lowering efect of metformin and increases OCT1 mRNA levels in healthy participants. Clin. Pharmacol. Ther. 89, 416-421 (2011).
17. Surekha, V., Peter, J.V., Jeyaseelan, L. & Cherian, A.M. Drug interaction: rifampicin and glibenclamide. Natl. Med. J. India 10, 11-12 (1997).
18. Niemi, M., Backman, J.T., Neuvonen, M., Neuvonen, P.J. & Kivistö, K.T. Rifampin decreases the plasma concentrations and efects of repaglinide. Clin. Pharmacol. Ther. 68, 495-500 (2000).
19. Park, J.Y., Kim, K.A., Park, P.W., Park, C.W. & Shin, J.G. Efect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clin. Pharmacol. Ther. 74, 334-340 (2003).
20. Zheng, H.X., Huang, Y., Frassetto, L.A. & Benet, L.Z. Elucidating rifampin's inducing and inhibiting efects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the diferential efects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin. Pharmacol. Ther. 85, 78-85 (2009).
21. Bidstrup, T.B., Stilling, N., Damkier, P., Scharling, B., Thomsen, M.S. & Brøsen, K. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur. J. Clin. Pharmacol. 60, 109-114 (2004).
22. Lau, Y.Y., Huang, Y., Frassetto, L. & Benet, L.Z. efect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther. 81, 194-204 (2007).
23. Bhalla, S., Ozalp, C., Fang, S., Xiang, L. & Kemper, J.K. Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha. Functional implications in hepatic cholesterol and glucose metabolism. J. Biol. Chem. 279, 45139-45147 (2004).
24. Waterhouse, M., Wilson, C., White, V.L. & Chowdhury, T.A. Resolution of insulin-requiring diabetes after cessation of chemotherapy for tuberculosis. J. R. Soc. Med. 98, 270-271 (2005).
25. Atkin, S.L., Masson, E.A., Bodmer, C.W., Walker, B.A. & White, M.C. Increased insulin requirement in a patient with type 1 diabetes on rifampicin. Diabet. Med. 10, 392 (1993).
26. Dooley, K.E. & Chaisson, R.E. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect. Dis. 9, 737-746 (2009).
27. Dong, B. et al. Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc. Natl. Acad. Sci. U.S.A. 106, 18831-18836 (2009).
28. Gao, J., He, J., Zhai, Y., Wada, T. & Xie, W. The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. J. Biol. Chem. 284, 25984-25992 (2009).
29. Rezen, T., Tamasi, V., Lövgren-Sandblom, A., Björkhem, I., Meyer, U.A. & Rozman, D. Efect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse livers. BMC Genomics 10, 384 (2009).
30. Lewis, R.J. & Mohr, J.F. 3rd. Dysglycaemias and fuoroquinolones. Drug Saf. 31, 283-292 (2008).
31. Kodama, S., Moore, R., Yamamoto, Y. & Negishi, M. Human nuclear pregnane X receptor cross-talk with CREB to repress cAMP activation of the glucose-6-phosphatase gene. Biochem. J. 407, 373-381 (2007).
32. Zhou, J. et al. A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J. Biol. Chem. 281, 15013-15020 (2006).
33. Kodama, S., Koike, C., Negishi, M. & Yamamoto, Y. Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol. Cell. Biol. 24, 7931-7940 (2004).
34. Leturque, A., Brot-Laroche, E. & Le Gall, M. GLUT2 mutations, translocation, and receptor function in diet sugar managing. Am. J. Physiol. Endocrinol. Metab. 296, E985-E992 (2009).
35. Roche, T.E. & Hiromasa, Y. Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer. Cell. Mol. Life Sci. 64, 830-849 (2007).
36. Gao, J. & Xie, W. Pregnane X receptor and constitutive androstane receptor at the crossroads of drug metabolism and energy metabolism. Drug Metab. Dispos. 38, 2091-2095 (2010).
37. Preiss, D. & Sattar, N. Statins and the risk of new-onset diabetes: a review of recent evidence. Curr. Opin. Lipidol. 22, 460-466 (2011).
38. Samaras, K. The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care. Curr. HIV/AIDS Rep. 9, 206-217 (2012).
39. Howe, K., Sanat, F., Thumser, A.E., Coleman, T. & Plant, N. The statin class of HMG-CoA reductase inhibitors demonstrate diferential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes. Xenobiotica. 41, 519-529 (2011).
40. He, J. et al. PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice. Diabetes (2013); e-pub ahead of print 24 January 2013.
41. Arpiainen, S. et al. Coactivator PGC-1alpha regulates the fasting inducible xenobiotic-metabolizing enzyme CYP2A5 in mouse primary hepatocytes. Toxicol. Appl. Pharmacol. 232, 135-141 (2008).
42. Wang, X. & Seed, B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res. 31, e154 (2003).
43. Dai, M. et al. Evolving gene/transcript defnitions signifcantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33, e175 (2005).
44. Buler, M. et al. Energy-sensing factors coactivator peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) and AMP-activated protein kinase control expression of infammatory mediators in liver: induction of interleukin 1 receptor antagonist. J. Biol. Chem. 287, 1847-1860 (2012).